- Home
- KZR vs SCLX Comparison
KZR vs SCLX Comparison
Compare KZR & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- SCLX
- Stock Information
- Founded
- KZR 2015
- SCLX 2011
- Country
- KZR United States
- SCLX United States
- Employees
- KZR N/A
- SCLX N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- KZR Health Care
- SCLX Health Care
- Exchange
- KZR Nasdaq
- SCLX Nasdaq
- Market Cap
- KZR 29.7M
- SCLX 35.7M
- IPO Year
- KZR 2018
- SCLX N/A
- Fundamental
- Price
- KZR $3.88
- SCLX $18.40
- Analyst Decision
- KZR Hold
- SCLX Strong Buy
- Analyst Count
- KZR 2
- SCLX 3
- Target Price
- KZR $9.00
- SCLX $367.50
- AVG Volume (30 Days)
- KZR 34.0K
- SCLX 248.0K
- Earning Date
- KZR 08-13-2025
- SCLX 08-13-2025
- Dividend Yield
- KZR N/A
- SCLX N/A
- EPS Growth
- KZR N/A
- SCLX N/A
- EPS
- KZR N/A
- SCLX N/A
- Revenue
- KZR N/A
- SCLX $44,236,000.00
- Revenue This Year
- KZR N/A
- SCLX $89.26
- Revenue Next Year
- KZR N/A
- SCLX $203.95
- P/E Ratio
- KZR N/A
- SCLX N/A
- Revenue Growth
- KZR N/A
- SCLX N/A
- 52 Week Low
- KZR $3.62
- SCLX $3.60
- 52 Week High
- KZR $9.18
- SCLX $42.53
- Technical
- Relative Strength Index (RSI)
- KZR 39.10
- SCLX 56.44
- Support Level
- KZR $3.84
- SCLX $17.35
- Resistance Level
- KZR $4.10
- SCLX $19.73
- Average True Range (ATR)
- KZR 0.14
- SCLX 2.03
- MACD
- KZR 0.01
- SCLX -0.40
- Stochastic Oscillator
- KZR 13.16
- SCLX 27.97
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.